Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention
22 Mai 2024 - 1:00PM
Entero Therapeutics, Inc. (formerly First Wave BioPharma,
Inc.) (Nasdaq: ENTO) (“Entero” or the “Company”), a late
clinical-stage biopharmaceutical company focused on the development
of targeted, non-systemic therapies for gastrointestinal (GI)
diseases, today announced that it will present at the 2024 BIO
International Convention which will be held June 3-6, 2024, in San
Diego, California.
Event: |
BIO International Convention |
Date: |
June 3-6, 2024 |
Presentations: |
Tuesday, June 4 at 10:30 a.m. PDT |
Location: |
Company Presentation Theater 4 |
Registration: |
https://convention.bio.org/registration |
To schedule a meeting at the BIO International
Convention with Entero, please submit a meeting request through the
BIO One-on-One Partnering™ platform.
For more information about Entero Therapeutics,
visit www.enterothera.com and connect on X and LinkedIn.
About Entero Therapeutics
Entero Therapeutics, Inc. (formerly First Wave BioPharma) is a
late clinical-stage biopharmaceutical company focused on the
development of targeted, non-systemic therapies for
gastrointestinal (GI) diseases. The Company’s programs address
significant unmet needs in GI health and include: latiglutenase, a
Phase 3-ready, potentially first-in-class, targeted, oral
biotherapeutic for celiac disease; capeserod, a selective 5-HT4
receptor partial agonist for indications including gastroparesis;
and adrulipase, a recombinant lipase enzyme designed to enable the
digestion of fats and other nutrients in cystic fibrosis and
chronic pancreatitis patients with exocrine pancreatic
insufficiency. For more information
visit www.enterothera.com.
Forward-Looking Statements This press
release may contain certain statements relating to future results
which are forward-looking statements. It is possible that the
Company’s actual results and financial condition may differ,
possibly materially, from the anticipated results and financial
condition indicated in these forward-looking statements, depending
on factors including whether any financing or licensing transaction
may be completed, completed with different terms, in an untimely
manner, or not at all; whether the Company will be able to realize
the expected benefits of its acquisition of ImmunogenX; the
Company’s ability to integrate the assets and contemplated
commercial operations acquired from ImmunogenX into the Company’s
business; whether results obtained in preclinical and nonclinical
studies and clinical trials will be indicative of results obtained
in future clinical trials; whether preliminary or interim results
from a clinical trial will be indicative of the final results of
the trial; whether the Company will be able to maintain compliance
with Nasdaq’s continued listing criteria and the effect of a
delisting from Nasdaq on the market for the Company’s securities;
the size of the potential markets for the Company’s drug candidates
and its ability to service those markets; the effects of the First
Wave Bio, Inc. acquisition, the related settlement and their effect
on the Company’s business, operating results and financial
prospects; and the Company’s current and future capital
requirements and its ability to raise additional funds to satisfy
its capital needs. Additional information concerning the Company
and its business, including a discussion of factors that could
materially affect the Company’s financial results are contained in
the Company’s Annual Report on Form 10-K for the year ended
December 31, 2023, filed with the Securities and Exchange
Commission (“SEC”) on March 29, 2024, as well as the Company’s
subsequent filings with the SEC, including its proxy statements on
Schedule 14A, Quarterly Report on Form 10-Q and Current Reports on
Form 8-K. All forward-looking statements included in this press
release are made only as of the date of this press release, and we
do not undertake any obligation to publicly update or correct any
forward-looking statements to reflect events or circumstances that
subsequently occur or of which we hereafter become aware.
For more information: Entero Therapeutics,
Inc. 777 Yamato Road, Suite 502 Boca Raton, FL
33431 Phone: (561)
589-7020 info@enterothera.com
Media contact:
Russo Partners David Schull or Liz
Phillips (347)
956-7697 david.schull@russopartnersllc.com elizabeth.phillips@russopartnersllc.com
Entero Therapeutics (NASDAQ:ENTO)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Entero Therapeutics (NASDAQ:ENTO)
Historical Stock Chart
Von Dez 2023 bis Dez 2024